Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAURA
2018-001061-16Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Jun 2018; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001061-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001061-16.